Silo Pharma Announces Positive Study Results of SPU- 21 for Arthritis

Stock Information for Silo Pharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Silo Pharma Inc.

Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer's Disease Therapeutic
Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic
Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain
Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD
Silo Wellness Announces Extension of Kaya/NUGL LOI; Annual Filings Delay
Silo Pharma's SP-26 Ketamine Implant Demonstrates Successful Drug Delivery
Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.